NANOBIOTIX (NANO.PA)
FR0011341205 - Common Stock
Overall NANO gets a fundamental rating of 1 out of 10. We evaluated NANO against 81 industry peers in the Biotechnology industry. NANO has a bad profitability rating. Also its financial health evaluation is rather negative. NANO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
NANO had negative earnings in the past year.
In the past year NANO has reported a negative cash flow from operations.
In the past 5 years NANO always reported negative net income.
In the past 5 years NANO always reported negative operating cash flow.
1.2 Ratios
The profitability ratios for NANO are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NANO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NANO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NANO has about the same amount of shares outstanding.
The number of shares outstanding for NANO has been increased compared to 5 years ago.
NANO has a worse debt/assets ratio than last year.
2.2 Solvency
NANO has an Altman-Z score of -6.99. This is a bad value and indicates that NANO is not financially healthy and even has some risk of bankruptcy.
NANO has a worse Altman-Z score (-6.99) than 86.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.99 |
ROIC/WACCN/A
WACC6.97%
2.3 Liquidity
A Current Ratio of 1.38 indicates that NANO should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.38, NANO is doing worse than 78.38% of the companies in the same industry.
A Quick Ratio of 1.38 indicates that NANO should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.38, NANO is doing worse than 74.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.38 |
3. Growth
3.1 Past
The earnings per share for NANO have decreased strongly by -20.82% in the last year.
Looking at the last year, NANO shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y-20.82%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-84.96%
Revenue growth 1Y-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to decrease by -16.02% on average over the next years. This is quite bad
The Revenue is expected to grow by 104.86% on average over the next years. This is a very strong growth
EPS Next Y37.19%
EPS Next 2Y26.44%
EPS Next 3Y14.28%
EPS Next 5Y-16.02%
Revenue Next Year1362.92%
Revenue Next 2Y321.11%
Revenue Next 3Y142.57%
Revenue Next 5Y104.87%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NANO. In the last year negative earnings were reported.
Also next year NANO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NANO's earnings are expected to grow with 14.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.44%
EPS Next 3Y14.28%
5. Dividend
5.1 Amount
NANO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NANOBIOTIX
EPA:NANO (9/22/2023, 7:00:00 PM)
8.12
+0.32 (+4.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap283.01M
Analysts89.09
Price Target11.12 (36.95%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)6.86%
PT rev (3m)14.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.35%
EPS NY rev (3m)36.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-19.84%
Revenue NY rev (3m)1509.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.64
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1.06
OCFYN/A
SpSN/A
BVpS-0.78
TBVpS-0.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 6.2% | ||
| Cap/Sales | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.38 | ||
| Altman-Z | -6.99 |
F-Score1
WACC6.97%
ROIC/WACCN/A
Cap/Depr(3y)9.08%
Cap/Depr(5y)38.14%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y-20.82%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-84.96%
EPS Next Y37.19%
EPS Next 2Y26.44%
EPS Next 3Y14.28%
EPS Next 5Y-16.02%
Revenue growth 1Y-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
Revenue Next Year1362.92%
Revenue Next 2Y321.11%
Revenue Next 3Y142.57%
Revenue Next 5Y104.87%
EBIT growth 1Y11.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.1%
EBIT Next 3Y-17.89%
EBIT Next 5YN/A
FCF growth 1Y-23.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.21%
OCF growth 3YN/A
OCF growth 5YN/A